r-14

Amchem R 14 is a biochemical.

Fluprostenol isopropyl ester, a potent agonist of the F-series prostaglandin receptor, serves as a prodrug utilized clinically as an ocular hypotensive agent for glaucoma treatment. An impurity, 13(R),14(R)-epoxy fluprostenol isopropyl ester, arises during its production, existing as a chiral enantiomer of the epoxide. The pharmacological properties of this specific enantiomer have yet to be thoroughly investigated.

14:0 Hemi BMP (S,R) ammonium is a bis(monoacylglycerol) phosphate (BMP) compound.

15-Nor-14-oxolabda-8(17),12-dien-18-oic acid is a useful organic compound for research related to life sciences and the catalog number is T126495.

SMARCA2 degrader-3 (compound I-323) is a PROTAC molecule designed to target and degrade the SMARCA2 protein. In A549 cells, it exhibits a degradation half-maximal concentration (DC50) of less than 100 nM and achieves a maximum degradation rate (Dmax%) greater than 90% after 24 hours of treatment.

FR-145715 is a histamine H2 receptor antagonist characterized by its specific anti-Helicobacter pylori activity. This compound is utilized in the study of gastric lesions.

FGFR1inhibitor-14 (compound 28) is an FGFR1 inhibitor used in cancer research.

PROTAC ER Degrader-14 (compound 86) is a PROTAC-type estrogen receptor/ERR degrader. It comprises an E3 ubiquitin ligase ligand (blue part) (S)-Deoxy-thalidomide, a PROTAC linker (black part) N-Boc-piperazine, and a target protein ligand (red part) ER ligand-6. The combination of the E3 ligase and linker forms tert-Butyl (S)-4-(2-(2,6-dioxopiperidin-3-yl)-1-oxoisoindolin-5-yl)piperazine-1-carboxylate.

ARCher-142 (compound S8) is a potent inhibitor of tankyrase. It selectively binds to ARC4 with an efficacy of 8 µM.

Aurora kinase inhibitor-14 (Compound 79) is an orally active and highly selective inhibitor of Aurora kinases, effectively inhibiting both Aurora A and Aurora B with IC50 values of 0.5 nM and 1.2 nM, respectively. It binds to the ATP binding site of Aurora kinases, blocking chromosome separation during mitosis and inducing apoptosis in tumor cells. Aurora kinase inhibitor-14 shows potential for research in various solid tumors and hematologic malignancies, such as non-small cell lung cancer, breast cancer, and acute myeloid leukemia.

AHR-14310C is a long-acting and nonsedating H1-antihistamine.

SR-140603, the less potent enantiomer of SR 140333, is used as the negative control.

HMR-1426 is gastric emptying inhibitor. HMR1426 shows an anorectic potential in rats and decreased body weight and fat mass. This was achieved solely by reducing food intake without influencing overall energy expenditure or behavior.

DSR-141562 is a new compound that can be taken orally and has a specific ability to inhibit phosphodiesterase 1 (PDE1) in the brain. This compound exhibits a preference for inhibiting human PDE1B, with an IC50 value of 43.9 nM. It also shows moderate inhibition of human PDE1A (IC50 = 97.6 nM) and PDE1C (IC50 = 431.8 nM). DSR-141562 is particularly useful in the study of positive symptoms, negative symptoms, and cognitive impairments associated with schizophrenia.

TR-14035 (MDK-1191) is a dual antagonist of α4β7/α4β1 integrins (IC50s: 7/87nM).

SCR-1481B1 (c-Met inhibitor 2) has activity against cancers dependent on Met activation and also has activity against cancers as a VEGFR inhibitor

KRAS inhibitor-14 is a potent inhibitor of KRAS G12C (IC50: 0.249 μM). KRAS inhibitor-14 exhibited p-ERK inhibition in MIA PaCA-2, A549 cells with IC50s of 1.12, >33.3 μM, respectively. KRAS inhibitor-14 has potential to be investigated in pancreatic, colorectal and lung cancers.

HIV-1 inhibitor-14 is a potent, broad-spectrum inhibitor of HIV-1 non-nucleoside reverse transcriptase (RT) (IC50=0.14 μM for HIV-1 RT). HIV-1 inhibitor-14 inhibits both wild-type and drug-resistant HIV-1 strains (EC50: 5.79-28.3 nM).

MR-1452 is a kappa opiate receptor antagonist. FOR RESEARCH USE ONLY

sEH inhibitor-14, a benzoxazolone-5-urea analogue, acts as an efficient soluble Epoxide Hydrolase (sEH) inhibitor, demonstrating significant activity with an IC50 value of 0.39 nM.

PROTAC BRD4 Degrader-14, a PROTAC (Proteolysis Targeting Chimera) linked by ligands to von Hippel-Lindau and BRD4, exhibits IC50 values of 1.8 nM and 1.7 nM for BRD4 BD1 and BD2, respectively. This compound effectively degrades the BRD4 protein in PC3 prostate cancer cells [1].

PI3K/mTOR Inhibitor-14 (compound Y-2) is a dual inhibitor of PI3K and mTOR, with IC50 values of 171.4 nM and 10.1 nM, respectively, and exhibits antitumor activities [1].

mTOR Inhibitor-14 (compound 14c) is a potent inhibitor of mTOR with minimal inhibition of CYP2C8 and has demonstrated the capability to inhibit tumor growth [1].

Compound 9, 15-Nor-14-oxolabda-8(17),12E-diene-18-oic acid, is an isolated compound derived from the roots of Chloranthus spicatus [1].